trial

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

NCTId NCT02281773
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Completed
Enrollment 518 (actual)
Sponsored by Boehringer Ingelheim
Primary completion 2016-05-26
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Completed
Enrollment
518 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2014-11-10
Primary completion
2016-05-26
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
BI 409306 100 mg QDBI 498306 50 mg QDBI 498306 25 mg QDBI 409306 10 mg QD

Sponsors

Boehringer IngelheimLead Sponsor

Sites

43 total
Little Rock, United StatesCerritos, United StatesGarden Grove, United StatesLos Angeles, United StatesNational City, United StatesOrange, United StatesSan Diego, United StatesTorrance, United StatesWashington D.C., United StatesLauderhill, United StatesMaitland, United StatesNorth Miami, United States

Linked catalysts

1
A Study to Investigate the Efficacy, Safety and Tolerability of Four Different D — primary completion2016-05-26

Facts & assertions

4 sourced
Enrollment
518
Phase
PHASE2
Primary Completion Date
2016-05-26
Status
COMPLETED
relationships
The graph out of here
drug
BI 409306 100 mg QD
drug
BI 498306 50 mg QD
drug
BI 498306 25 mg QD
drug
BI 409306 10 mg QD
drug
lead_sponsor
Boehringer Ingelheim
company
indication
Schizophrenia
indication
Schizophrenia
indication